39 results about "Blood creatinine" patented technology

The invention discloses application of an RNF130 activator in preparation of a medicine for preventing and / or treating acute kidney injury, and belongs to the technical field of biological medicine. The invention provides an application of an RNF130 activator in preparation of a medicine for preventing or treating renal ischemia-reperfusion injury, the RNF130 activator can improve the renal function of a mouse suffering from renal ischemia-reperfusion injury, improve the levels of serum creatinine, urea nitrogen and cystatin C, reduce the levels of kidney injury markers KIM-1 and LCN2, reduce renal tubule injury, improve the renal function of the mouse suffering from renal ischemia-reperfusion injury, improve the renal function of the mouse suffering from renal ischemia-reperfusion injury and improve the renal function of the mouse suffering from renal ischemia-reperfusion injury and the renal function of the mouse suffering from renal ischemia-reperfusion injury. Therefore, the compound plays a role in preventing and treating the kidney ischemia reperfusion injury, and a new target is provided for preparing the medicine for preventing and treating the acute kidney injury.

The invention discloses application of oligopeptide in preparation of a medicine for treating and / or preventing diabetic nephropathy. The oligopeptides comprise oligopeptides with the amino acid sequence of SEQ ID NO: 1: LNLYP and derivative sequences or conservative substitution variants of the oligopeptides. The oligopeptide can significantly improve renal function indexes of mice with diabetic nephropathy, such as UACR, serum creatinine, urea nitrogen and the like, enhance podocyte barrier integrity and inhibit accumulation of advanced glycosylation end products AGEs in kidney tissues, and provides a basis for development of novel drugs for treating diabetic nephropathy.

The invention provides a clinical rehabilitation data management and evaluation system for a rhabdomyolysis patient, and relates to a medical information management system. The system comprises an index acquisition module, a rate detection module, a curvature analysis module, a node identification module and a trend construction module. According to the method, the rate difference sequence of creatine kinase and myohemoglobin and the curvature sequence of urine sodium and serum creatinine are compositely calculated, the limitation of traditional single-parameter static analysis is broken through, the dynamic capture of a multi-index collaborative trend is realized, and a joint evolution label system is constructed by combining the consistency judgment of creatine kinase and blood potassium concentration change directions; according to the method, multi-system interaction risk nodes are accurately positioned, statistics is performed on direction consistency proportional distribution of myoglobin and serum creatinine in an association time period, discrete parameter association is converted into a dynamic visual model, and the problems of data discreteness misjudgment and collaborative evolution mode splitting in the traditional technology are solved. And a multi-dimensional dynamic evaluation framework of the rhabdomyolysis rehabilitation process is provided for clinic.

The invention provides a traditional Chinese medicine composition for treating nephropathy as well as a preparation method and application thereof, and the anti-renal fibrosis effect is remarkably improved by optimizing a leech extraction process and a novel preparation technology. Animal experiments show that urine protein of model animals can be reduced by 67% and serum creatinine can be reduced by 42% after 12 weeks of continuous administration. Clinical tests prove that the traditional Chinese medicine composition has a definite curative effect on IgA nephropathy, membranous nephropathy and the like, and a new choice is provided for treating chronic kidney diseases.

The invention belongs to the technical field of reproductive medicine and clinical metabolism intervention, and particularly relates to a group of markers for diagnosing unexplained recurrent abortion and application thereof. Aiming at the clinical pain point that unexplained recurrent abortion (URSA) lacks accurate metabolic typing diagnosis indexes and targeted treatment means, based on detection of a large number of clinical samples and verification of cell experiments, direct association between down-regulation of levels of choline related metabolites and trimethylamine oxide (TMAO) of decidua tissues and the RSA is disclosed for the first time; the core effect of TMAO in-situ synthesis of decidua stromal cells (DSC) in regulation and control of the decidualization process is determined; meanwhile, an RSA indication screening system of joint detection of serum creatinine and decidua choline metabolism is constructed, a targeted TMAO targeted intervention scheme is formed in a matched mode, a diagnosis and treatment closed loop of RSA from precise typing to targeted treatment is achieved, and a brand new technical path is provided for clinically solving the URSA diagnosis and treatment problem.

The invention discloses a blood creatinine content information detection method and system, and the method comprises the steps: obtaining a face video image, determining the absorbance data of different components in blood based on the face video image, and determining the spectral information of different components based on the absorbance data; preprocessing the spectral information to obtain a blood component spectrogram; and inputting the spectrogram into a discrimination model, and outputting creatinine content information in the blood. The purpose of non-contact measurement of creatinine content information is achieved.

The application provides a clinical rehabilitation data management and evaluation system for rhabdomyolysis patients, and relates to a medical information management system.The system comprises an index acquisition module, a rate detection module, a curvature analysis module, a node identification module and a trend construction module.In the application, the rate difference sequence of creatine kinase and myoglobin and the curvature sequence of urine sodium and blood creatinine are combined to break through the limitations of traditional single-parameter static analysis, realize dynamic capture of multi-index collaborative trend, construct a joint evolution label system by combining the consistency discrimination of creatine kinase and blood potassium concentration change direction, accurately locate the multi-system interaction risk nodes, and statistically distribute the direction consistency proportion of myoglobin and blood creatinine in the correlation period, so as to convert the discrete parameter correlation into a dynamic visual model.The method solves the problems of data dispersion misjudgment and collaborative evolution mode fragmentation in the traditional technology, and provides a multi-dimensional dynamic evaluation framework for the rhabdomyolysis rehabilitation process in clinical practice.

The present invention belongs to the technical field of diabetic nephropathy drugs, and particularly relates to a traditional Chinese medicine composition for treating early diabetic nephropathy and a preparation method thereof. The traditional Chinese medicine composition comprises the following main components by weight: 20-40 parts of astragalus, 10-20 parts of pseudoginseng, 20-40 parts of raw rehmannia, 10-20 parts of cornus officinalis, 10-20 parts of winter mallow seeds, 10-20 parts of euryale ferox, 9-15 parts of morus alba bark, 10-20 parts of zedoaria, 3-6 parts of leeches, and 3-6 parts of scorpions. The traditional Chinese medicine composition combines kidney-tonifying and spleen-invigorating drugs with blood circulation-activating and collateral-dredging drugs, and is nutritious without being greasy, and attacks pathogens without damaging the body, thereby jointly achieving the functions of invigorating the spleen and replenishing qi, tonifying the kidney, activating blood circulation and dredging collaterals, and having significant therapeutic effects in lowering blood sugar and blood creatinine, improving symptoms of diabetic nephropathy, and improving the quality of life of patients.

The invention belongs to the field of pet food processing, and relates to a premix for improving the health of urinary tracts of pets. The premix comprises the following components in parts by weight: 25-35 parts of Chinese yams, 25-35 parts of poria cocos, 15-25 parts of dandelions, 15-25 parts of centella asiatica, 15-25 parts of semen plantaginis, 5-15 parts of rhizoma polygonati, 5-15 parts of dogwood and 5-15 parts of Chinese wolfberry fruits. By adding the premix disclosed by the invention into daily ration, the concentrations of cat blood creatinine, urea nitrogen and blood oxalic acid are reduced, the absorption and excretion of oxalic acid are influenced, and the formation of calcium oxalate calculi is prevented. The premix disclosed by the invention can relieve the kidney toxicity of sodium oxalate to cats, improve the physiological indexes of the kidneys, reduce the formation of calcium oxalate calculi and provide basic guarantee for the treatment of chronic urinary system diseases. The premix disclosed by the invention can be used for improving the urinary tract health of cats.

The invention discloses application of disulfiram in preparation of a medicine for treating UMOD gene mutation type autosomal dominant renal tubulointerstitial nephropathy, and belongs to the field of biomedicine. The application comprises the application of the disulfiram in preparation of the medicine for treating the hereditary tubulointerstitial nephropathy. According to the invention, a new pathogenic mutation UMOD c.106Cgt is identified; according to the invention, the pathogenicity of the gene is verified through a UMODH36Y mouse model constructed by CRISPR / Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats / CRISPR associated 9). DSF intervention is adopted, the serum creatinine and glomerular filtration rate (tGFR) of mice can be remarkably improved, and renal interstitial inflammation and fibrosis are relieved. The discovery prompts that the DSF realizes the therapeutic effect of renal function protection-inflammation inhibition-fibrosis relief in an ADTKD-UMOD animal model through targeted regulation of a pyroptosis pathway, a novel therapeutic strategy is provided for ADTKD-UMOD, and the clinical transformation period can be remarkably shortened due to the characteristic of new use of old medicines. The discovery lays an experimental foundation for developing a precise treatment scheme for the hereditary renal tubulointerstitial disease.

The application discloses an application of an RNF130 activator in preparation of a medicine for preventing and / or treating acute kidney injury, and belongs to the technical field of biological medicines.The application provides an application of the RNF130 activator in preparation of a medicine for preventing or treating kidney ischemia-reperfusion injury, and the RNF130 activator can improve kidney function of a mouse with kidney ischemia-reperfusion injury, improve levels of blood creatinine, urea nitrogen and cystatin C, reduce levels of kidney injury markers KIM-1 and LCN2, and reduce tubular injury, thereby playing a preventive and therapeutic role on kidney ischemia-reperfusion injury, and providing a new target for preparation of a medicine for preventing and treating acute kidney injury.

This invention relates to the field of biomedical technology, and more particularly to a biomarker set, staging model, and their applications for chronic kidney disease. This invention utilizes metabolomics data analysis to obtain a biomarker set based on serum creatinine. Then, through methodological optimization, a staging model for chronic kidney disease is constructed. This staging model is also used for staging chronic kidney disease, and the results are accurate, specific, precise, and highly sensitive. It eliminates the false positive problem of traditional serum creatinine-based methods and removes the influence of gender factors. Staging chronic kidney disease based on this model is more consistent with the disease's progression characteristics.

The ganoderma lucidum and mesona chinensis preparation is prepared from 10-100 g of ganoderma lucidum, 10-100 g of mesona chinensis (mesona chinensis), 10-100 g of rhizoma polygonati, 10-100 g of astragalus membranaceus, 10-100 g of dandelion, 10-100 g of herba cepbalanoplosis segeti, 10-100 g of fructus gardeniae, 10-100 g of honeysuckle, 10-100 g of pilea cavaleriei, 10-100 g of centipede, 10-100 g of cudrania cochinchinensis, 4-40 g of embroidery needle, 4-40 g of bitter The preparation can clear away heat and toxic materials, induce diuresis to alleviate edema, improve the immunity of a human body, effectively reduce serum creatinine, uric acid, blood pressure and blood sugar, improve the immunity of the human body, improve the immunity of the human body, reduce the toxic and side effects of the human body, reduce the toxic and side effects of the human body, reduce the toxic and side effects of the human body, and reduce the toxic and side effects of the human body. The traditional Chinese medicine composition has good treatment effects on uremia, nephritis, renal cyst, kidney stone, hepatitis B, cirrhosis, liver ascites, insomnia, asthma, pharyngitis, cough, cancerous diseases and cardia-cerebrovascular diseases.

The invention discloses application of mogroside V in preparation of an anti-renal fibrosis medicine, and belongs to the technical field of biological medicines. Experiments prove that the mogroside V can obviously improve the renal function of a mouse with renal fibrosis, and the serum creatinine and blood urea nitrogen levels are obviously reduced. Meanwhile, the compound can be used for effectively inhibiting the expression of fibrosis markers alpha-SMA and Fibronectin in renal tissues, and delaying the fibrosis process by up-regulating the expression level of an epithelial-mesenchymal transition marker E-cadherin. In addition, the mogroside V can also significantly reduce collagen deposition in kidney tissues, and plays a role in treating renal fibrosis. The traditional Chinese medicine composition has the advantages of safety, effectiveness, no side effect, good taste and the like when being used for preparing the anti-renal fibrosis medicine.

The invention discloses a method for non-invasive diagnosis of serum creatinine based on Raman spectrum.The method belongs to the crossing field of analysis and detection and biomedical engineering.The method comprises the steps that firstly, a part with flat skin and rich blood vessels is selected, cleaned and dried, then the best offset with the strongest correlation between a cortex depth Raman signal and creatinine is determined through OCT scanning, and the optimal offset is obtained; the method comprises the following steps of: acquiring a spectrum through an optical fiber probe of an mmu SORS system, performing pretreatment such as baseline correction and normalization on the acquired spectrum to extract a creatinine characteristic peak, establishing a PLS regression model to correct a spectrum-concentration relationship, and finally verifying through MARD and CEG A + B region data proportion indexes. According to the method, noninvasive precise serum creatinine detection is achieved through the mmu SORS technology, the problems that in the prior art, sensitivity is low and interference is large are solved by means of Raman spectrum molecular fingerprint features and OCT depth positioning, the change trend of serum creatinine is tracked in real time through continuous detection, and dynamic monitoring and personalized medical support are provided.

The invention discloses a construction method and application of an exacerbated acute kidney injury model, and belongs to the technical field of biomedicine. In particular discloses application of an Atg7 phosphorylation deficient mutant Atg7-T82A / T562A in construction of an exacerbated acute kidney injury (AKI) model. The mutant is delivered to the kidney of a mouse through an adeno-associated virus (AAV), phosphorylation modification of AMPK on Atg7 is specifically blocked, and in combination with an acute renal ischemia (ARI) model, serum creatinine and urea nitrogen levels can be remarkably improved, renal tubular necrosis and apoptosis can be aggravated, autophagosome formation can be reduced, and mitochondrial injury can be induced. The method has high specificity and high efficiency, and provides a key tool for mechanism research, drug toxicity evaluation and treatment strategy development of autophagy-related renal injury.

The invention discloses application of S100a9 as an acute kidney injury biomarker and a therapeutic target, and belongs to the technical field of biological medicine. The invention provides an application of an S100a9 inhibitor / antagonist in screening and preparing a product for preventing and / or treating acute kidney injury, and further provides an application of a reagent for detecting expression and / or activity of S100a9 in preparing a diagnosis and / or prognosis product for acute kidney injury. Results of the embodiment of the invention show that S100A9 can be obviously increased through ELISA detection within 6 hours after a cardiac surgery, is more sensitive than serum creatinine, and is beneficial to clinical early diagnosis and intervention; in sepsis, ischemia reperfusion and cis-platinum induced animal AKI models, the knockout of the S100a9 is proved to be capable of remarkably reducing expression of injury markers such as serum creatinine and KIM-1 and relieving the renal injury, so that the invention provides a new marker and a treatment target for the acute renal injury.

The present invention relates to the field of medical care informatics technology, and specifically to a standardized intelligent training method and system for peritoneal dialysis. The present invention first obtains the patient's physical function measurement during the training stage based on the time-series changes in the patient's blood creatinine concentration and urea nitrogen concentration during the training stage, as well as the overall distribution of the values ​​of vital capacity and resting heart rate corresponding to all tests; obtains the patient's training acceptance of the items to be analyzed during the training stage based on all training records and assessment results of the patient's items to be analyzed; further obtains the patient's training intensity requirement for the items to be analyzed during the training stage; and finally formulates a training plan for the patient's next training stage. The present invention better meets the patient's personalized needs during the training stage and improves the training effect of the training plan by fully considering the patient's physical function during the training stage and the patient's acceptance of the training project.

The present invention discloses the application of Penthorum chinense Pursh in the preparation of a medicament for treating elevated blood creatinine or a health product for preventing and treating elevated blood creatinine. The present invention discovers for the first time that the water extract of Penthorum chinense Pursh has good curative effects on the elevation of blood creatinine, blood uric acid, and blood urea nitrogen caused by primary chronic kidney diseases and abnormal glomerular filtration, especially specifically reduces the serum creatinine level, and can significantly improve the clinical symptoms of patients with renal hypercreatinemia; Penthorum chinense Pursh has the effects of clearing heat and detoxifying, dredging collaterals and resolving masses, and promoting diuresis and detumescence, has no obvious damage to liver function, and has a protective effect. Therefore, it has high safety and can be eaten as a health product in daily life for preventing and treating the elevation of blood creatinine.

The invention provides a traditional Chinese medicine composition for treating chronic renal failure as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for treating chronic renal failure is prepared from the following raw materials: rheum officinale, polygonum cuspidatum, leonurus, astragalus membranaceus, dandelion, poria cocos, plantain herb, herba lycopi, white mulberry root-bark, radix paeoniae alba and eclipta. The traditional Chinese medicine composition adjusts traditional Chinese medicine components, follows the compatibility principle of monarch, minister, assistant and guide and the structure theory, reasonably organizes medicines, enhances the curative effect, reduces toxic and side effects, comprehensively takes care of the illness state, improves the treatment effect of the traditional Chinese medicine composition on chronic renal failure, adjusts the abnormal levels of serum urea nitrogen and serum creatinine, and improves calcium and phosphorus metabolism disorder.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a kidney-protecting and blood stasis-removing mixture and a preparation method and application thereof. The kidney-protecting and blood stasis-eliminating mixture is composed of astragalus membranaceus, angelica sinensis, rhizoma bletillae, plantain herb, peach kernel, cooked rhubarb and scalded leech, the selected medicinal materials are appropriate in compatibility, the traditional Chinese medicine theory and the modern medicine theory are met, and the kidney-protecting and blood stasis-eliminating mixture has the effects of promoting blood circulation to remove blood stasis, tonifying kidney and spleen and eliminating dampness and heat. The kidney-protecting and blood stasis-eliminating mixture disclosed by the invention has remarkable curative effects on reducing serum creatinine, improving symptoms of chronic renal failure and acute renal failure, improving the life quality of patients and the like.

The invention discloses a pharmaceutical composition for treating chronic kidney disease stage 1-3 as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The composition consists of 40-60 parts of astragalus membranaceus, 40-60 parts of black soybeans, 8-12 parts of angelica sinensis, 24-36 parts of dogwood and 8-12 parts of rhodiola rosea. The preparation method comprises the following steps: pretreating the raw materials, soaking, boiling for several times and filtering to obtain a finished product. Based on the treatment principles of tonifying qi, activating blood, dredging collaterals and removing blood stasis in traditional Chinese medicine, the traditional Chinese medicine composition conforms to the pathogenesis of chronic kidney disease deficiency in root and excess in superficies, all the components synergistically play a role, the serum urea nitrogen, serum creatinine level and glomerular filtration rate of a patient can be improved and edema, weakness and other symptoms can be relieved by combining basic treatment, the total effective rate reaches 83.33%, and the traditional Chinese medicine composition is good in safety, easy and convenient to prepare and suitable for clinical application. The traditional Chinese medicine composition is suitable for long-term administration of patients with spleen and kidney qi deficiency and blood deficiency with stasis syndrome type chronic kidney diseases at 1-3 stages, and has good application value in treatment of related diseases.

The invention discloses an application of hexacosanol in preparation of a medicine for relieving and / or treating chronic kidney disease. Relates to the technical field of medicine products. It is found and proved for the first time that hexacosanol can effectively reduce serum creatinine (Scr) and urea nitrogen (BUN) levels of chronic kidney disease model animals and improve kidney pathological injuries, and shows a remarkable kidney protection effect. Besides, the invention provides a series of products containing hexacosanol, including pharmaceutical compositions for treating and / or relieving chronic kidney diseases and health products for assisting in improving and / or maintaining kidney health, and brand-new and safe natural active ingredient choices are provided for treatment and auxiliary management of chronic kidney diseases.

The invention belongs to the technical field of biology, and particularly relates to application of triple active ingredients in birch juice in relieving hyperuricemia. According to the invention, firstly, the influence of birch juice on the weight, blood uric acid, blood urea nitrogen, serum creatinine and visceral organ coefficient of a hyperuricemia mouse is evaluated through animal experiments; in order to reveal the potential mechanism of the active ingredients of the birch juice for relieving the hyperuricemia, the invention further explores the ability of three main active ingredients of betulin, betulinic acid and kaempferol in the birch juice for regulating and controlling the high-grade conformation of nucleic acid in a hyperuricemia-related gene promoter region; the molecular mechanism of the triple active components in the birch juice for relieving hyperuricemia is speculated and explained from the gene level. In conclusion, the invention provides a brand-new theoretical basis and mechanism elaboration of a gene level for relieving metabolic diseases by natural functional small molecules.

The present invention belongs to the field of pharmaceutical technology, and specifically discloses a biomarker for detecting kidney fibrosis-related diseases and its application. The biomarker includes ceruloplasmin in serum, or ceruloplasmin in serum and creatinine. Compared with other methods for diagnosing renal fibrosis, ceruloplasmin in serum has three major advantages: First, compared with conventional diagnostic markers (such as creatinine), ceruloplasmin can be detected to be up-regulated in the serum of patients with early chronic kidney diseases, and can be jointly detected with existing mature diagnostic markers; Second, compared with renal tissue pathological biopsy, using ceruloplasmin as a diagnostic marker is non-invasive, only a small amount or even a trace amount of patient serum is required, and it will not cause harm to the patient's physical health; Third, compared with the method of analyzing the metabolic components of urine by nuclear magnetic resonance, the method of detecting the biomarker in serum has a lower cost, a more flexible detection method, high timeliness and is easier to popularize.

The invention discloses a composition containing valsartan and fineglitazone and a preparation method of the composition, and relates to the technical field of pharmaceutical compositions.According to the composition, valsartan, fineglitazone, a curcumin phospholipid complex and L-arginine are scientifically proportioned, a three-dimensional kidney protection network is constructed, and the kidney protection effect is improved. Valsartan and fineglitazone cooperate to block excessive activation of RAAS, blood pressure is effectively reduced, glomerular hyperfiltration is relieved, aldosterone-mediated renal fibrosis and inflammatory response can be inhibited, on the basis, the curcumin phospholipid complex improves bioavailability of fat-soluble curcumin through a phospholipid carrier, and the bioavailability of fat-soluble curcumin is improved. The microencapsulated L-arginine can specifically enhance the activity of antioxidant enzymes in kidney tissues and relieve oxidative damage to renal tubular epithelial cells, and the microencapsulated L-arginine serves as an NO precursor substance, controls the slow release rate through an eudragit EPO coating, continuously supplements an NO synthetic substrate, repairs an NO signal channel of damaged vascular endothelial cells and reduces serum creatinine and urea nitrogen levels.

This invention belongs to the field of pet food processing and relates to a premix for improving the urinary tract health of pets. The premix contains the following components in parts by weight: 25-35 parts of Dioscorea opposita, 25-35 parts of Poria cocos, 15-25 parts of Taraxacum mongolicum, 15-25 parts of Centella asiatica, 15-25 parts of Plantago asiatica, 5-15 parts of Polygonatum sibiricum, 5-15 parts of Cornus officinalis, and 5-15 parts of Lycium barbarum. Adding this premix to the cat's diet reduces serum creatinine, blood urea nitrogen, and serum oxalate concentrations, affecting oxalate absorption and excretion, and preventing the formation of calcium oxalate stones. This premix can alleviate the nephrotoxicity of sodium oxalate in cats, improve renal physiological indicators, reduce the formation of calcium oxalate stones, and provide a basic guarantee for the treatment of chronic urinary system diseases. This premix can improve the urinary tract health of cats.

The present disclosure provides a Lactiplantibacillus plantarum strain for alleviating hyperuricemia and a combination and use thereof, and belongs to the technical field of microorganisms. The Lactiplantibacillus plantarum strain was deposited in the China Center for Type Culture Collection (CCTCC), Wuhan, China on Oct. 19, 2022, with an accession number of CCTCC NO: M20221596. The combination includes the Lactiplantibacillus plantarum strain BL-17, 0.01 wt % of a galacto-oligosaccharide, 0.01 wt % of an adenylic acid, and the balance of a sterilized skimmed milk solution. The combination according to the present disclosure can effectively alleviate the high serum uric acid levels in hyperuricemic rats, increase the urine uric acid levels in hyperuricemic rats, reduce the serum creatinine levels in hyperuricemic rats, reduce the serum urea nitrogen levels in hyperuricemic rats, and inhibit the activity of xanthine oxidase (XOD) in the serum and liver of hyperuricemic rats, and has an effect for alleviating hyperuricemia.

The invention discloses a traditional Chinese medicine composition for treating diabetic nephropathy as well as a preparation method and application thereof, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 250 to 400 parts of radix astragali seu hedysari, 350 to 500 parts of radix rehmanniae recen, 200 to 350 parts of rhizoma atractylodis macrocephalae stir-fried with bran, 50 to 200 parts of radix et rhizoma rhei, 200 to 350 parts of herba leonuri, 200 to 350 parts of radix angelicae sinensis, 200 to 350 parts of cortex phellodendri and 30 to 120 parts of scalded leech. Compared with radix astragali and rhizoma atractylodis macrocephalae capsules, the traditional Chinese medicine composition disclosed by the invention can more effectively reduce fasting blood glucose, blood urea nitrogen and serum creatinine of rats with diabetic nephropathy.

The invention relates to application of iron sucrose in prevention of transplanted kidney ischemia-reperfusion (I / R) injury. The safety and effectiveness of the iron sucrose in prevention of mouse kidney I / R injury are mainly investigated, the application of the iron sucrose in preparation of the medicine for prophylactically relieving the kidney I / R injury is provided, and mouse in-vivo tests show that the inflammatory response of the I / R kidney can be remarkably reduced by intravenous injection of 3.0 mg (150 mg / kg body weight) of the iron sucrose one day before an operation; according to the present invention, the serum creatinine and urea nitrogen levels of mice are reduced, the kidney injury caused by I / R is effectively and safely reduced, the important basis is provided for the clinical application of the iron sucrose before the operation of the kidney transplantation recipient so as to reduce the ischemia-reperfusion injury during the transplantation process, and the new strategy is provided for reducing the delayed recovery of the transplanted kidney function and improving the long-term survival of the transplanted kidney.